Brookstone Capital Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-10,248
Closed -$1.04M 1226
2025
Q4
$1.04M Buy
10,248
+148
+1% +$11.9K 0.01% 618
2025
Q3
$553K Buy
10,100
+46
+0.5% +$2.3K 0.01% 785
2025
Q2
$534K Sell
10,054
-535
-5% -$27.2K 0.01% 725
2025
Q1
$458K Buy
10,589
+713
+7% +$36.1K 0.01% 735
2024
Q4
$555K Sell
9,876
-5,077
-34% -$316K 0.01% 662
2024
Q3
$1.02M Buy
14,953
+2,147
+17% +$121K 0.02% 515
2024
Q2
$632K Buy
12,806
+7,201
+128% +$396K 0.01% 594
2024
Q1
$387K Buy
+5,605
New +$355K 0.01% 691
2023
Q3
Sell
-2,780
Closed -$252K 846
2023
Q2
$252K Buy
+2,780
New +$217K 0.01% 739
2021
Q4
Sell
-2,511
Closed -$244K 762
2021
Q3
$244K Sell
2,511
-11
-0.4% -$1.16K ﹤0.01% 653
2021
Q2
$289K Buy
+2,522
New +$301K 0.01% 599

Other funds holding EXAS

Brookstone Capital Management's EXAS Position: Q1 2026 in Review

Brookstone Capital Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 10,248 shares — an estimated $1.04M sold.

Brookstone Capital Management first reported a position in EXAS in Q2 2021 and held it in 11 quarters. The position peaked at $1.04M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Brookstone Capital Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Brookstone Capital Management sold 10,248 Exact Sciences shares in Q1 2026, an estimated $1.04M.
  • Brookstone Capital Management first reported a position in Exact Sciences in Q2 2021 and held it in 11 quarters.
  • Brookstone Capital Management's Exact Sciences position peaked at $1.04M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Brookstone Capital Management's 13F filing for Q1 2026, filed 16 Apr 2026.